NASDAQ:OVID Ovid Therapeutics (OVID) Stock Price, News & Analysis → Don’t make this retirement mistake (From Sasco Gold LLC) (Ad) Free OVID Stock Alerts $3.10 +0.14 (+4.73%) (As of 06/10/2024 ET) Add Compare Share Share Today's Range$2.89▼$3.1250-Day Range$2.96▼$3.3452-Week Range$2.57▼$4.14Volume134,554 shsAverage Volume172,477 shsMarket Capitalization$219.91 millionP/E RatioN/ADividend YieldN/APrice Target$8.08 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Ovid Therapeutics alerts: Email Address Ovid Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside160.8% Upside$8.08 Price TargetShort InterestBearish4.95% of Float Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$50,364 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.85) to ($0.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.85 out of 5 starsMedical Sector190th out of 904 stocksPharmaceutical Preparations Industry81st out of 427 stocks 3.4 Analyst's Opinion Consensus RatingOvid Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOvid Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Ovid Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted4.95% of the float of Ovid Therapeutics has been sold short.Short Interest Ratio / Days to CoverOvid Therapeutics has a short interest ratio ("days to cover") of 14.6, which indicates bearish sentiment.Change versus previous monthShort interest in Ovid Therapeutics has recently increased by 1.06%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOvid Therapeutics does not currently pay a dividend.Dividend GrowthOvid Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOvid Therapeutics has received a 71.15% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Clinical research services for Epilepsy or seizures" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Ovid Therapeutics is -0.85. Previous Next 1.1 News and Social Media Coverage Search Interest4 people have searched for OVID on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Ovid Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ovid Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,364.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.30% of the stock of Ovid Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.24% of the stock of Ovid Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ovid Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ovid Therapeutics are expected to grow in the coming year, from ($0.85) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ovid Therapeutics is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ovid Therapeutics is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOvid Therapeutics has a P/B Ratio of 2.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Ovid Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Sasco Gold LLCDon’t make this retirement mistakeIf you have over $100,000 in your 401K or IRA… Then listen closely… Your money is rotting away, and you might not even realize it.Reserve your seat here. About Ovid Therapeutics Stock (NASDAQ:OVID)Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.Read More OVID Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OVID Stock News HeadlinesJune 1, 2024 | americanbankingnews.comOvid Therapeutics Inc. (NASDAQ:OVID) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 28, 2024 | investorplace.com3 Sorry Penny Stocks to Sell in May While You Still CanMay 20, 2024 | markets.businessinsider.comBuy Rating for Ovid Therapeutics Based on Novel SE Drug Candidates OV329 and OV350May 20, 2024 | investorplace.comWall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024May 16, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Ovid Therapeutics (OVID)May 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Ovid Therapeutics Amid Strong Financials and Promising Drug PipelineMay 14, 2024 | investorplace.comOVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q1 2024May 14, 2024 | globenewswire.comOvid Therapeutics Reports Business Updates and First Quarter 2024 Financial ResultsMay 13, 2024 | globenewswire.comOvid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 7, 2024 | markets.businessinsider.comCracking The Code: Understanding Analyst Reviews For Ovid TherapeuticsApril 30, 2024 | nasdaq.comHC Wainwright & Co. Initiates Coverage of Ovid Therapeutics (OVID) with Buy RecommendationApril 18, 2024 | finance.yahoo.comWe Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business GrowthApril 5, 2024 | msn.comOvid Therapeutics gains on bullish view at WedbushApril 4, 2024 | globenewswire.comOvid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceApril 2, 2024 | msn.comMarinus Pharmaceuticals Stands Firm in Patent Dispute Over Key Epilepsy TreatmentMarch 29, 2024 | bizjournals.comMarinus Pharmaceuticals' patent battle with New York firm over seizure therapy takes new twistMarch 22, 2024 | investing.comOvid therapeutics CEO acquires $50k in company stockMarch 22, 2024 | finance.yahoo.comOvid Therapeutics Reaches US$197m Market Cap Benefiting Insider Stock BuyingMarch 17, 2024 | insidermonkey.com5 Oversold Biotech Stocks To Buy Right NowMarch 13, 2024 | markets.businessinsider.comOvid Therapeutics: Strong Buy Rating on Robust Pipeline and Strategic PartnershipsMarch 13, 2024 | news.yahoo.comOvid gas station, state and local officials dealing with contaminated fuel problemMarch 13, 2024 | msn.comOvid gas station shut down after discovery of water inside pumpsMarch 11, 2024 | markets.businessinsider.comTD Cowen Sticks to Its Buy Rating for Ovid Therapeutics (OVID)March 9, 2024 | finance.yahoo.comOVID Oct 2024 7.500 callMarch 8, 2024 | benzinga.comRecap: Ovid Therapeutics Q4 EarningsSee More Headlines Receive OVID Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/10/2024Next Earnings (Estimated)8/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OVID CUSIPN/A CIK1636651 Webwww.ovidrx.com Phone(646) 661-7661FaxN/AEmployees40Year Founded2014Price Target and Rating Average Stock Price Target$8.08 High Stock Price Target$11.00 Low Stock Price Target$3.50 Potential Upside/Downside+160.8%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,340,000.00 Net Margins-10,691.14% Pretax Margin-10,691.35% Return on Equity-53.62% Return on Assets-37.76% Debt Debt-to-Equity Ratio0.18 Current Ratio10.47 Quick Ratio10.47 Sales & Book Value Annual Sales$390,000.00 Price / Sales563.88 Cash FlowN/A Price / Cash FlowN/A Book Value$1.24 per share Price / Book2.50Miscellaneous Outstanding Shares70,940,000Free Float61,509,000Market Cap$219.91 million OptionableOptionable Beta0.59 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Jeremy Max Levin Ba Zoology (Age 71)Dphil, Mb Bchir, President, CEO & Chairman Comp: $1.03MMr. Jeffrey A. Rona (Age 56)Chief Business and Financial Officer Comp: $761.24kMr. Thomas Michael Perone J.D. (Age 59)M.B.A., General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $745.71kMr. Jason Tardio M.B.A. (Age 47)Chief Operating Officer Comp: $652.84kMr. Simon D. Kelner (Age 50)Chief Human Resources Officer Dr. Dirk Haasner (Age 59)Senior Vice President of Global Manufacturing & CMC QA Comp: $416.95kDr. Todd F. Baumgartner M.D.M.P.H., Senior Vice President of Regulatory AffairsDr. Julia Tsai Ph.D. (Age 49)Senior Vice President of Clinical Development Ms. Meg AlexanderChief Strategy OfficerDr. Manoj Malhotra M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsImmunicNASDAQ:IMUXBioDelivery Sciences InternationalNASDAQ:BDSIABIVAX Société AnonymeNASDAQ:ABVXCentessa PharmaceuticalsNASDAQ:CNTACogent BiosciencesNASDAQ:COGTView All CompetitorsInsiders & InstitutionsBVF Inc. ILSold 2,997,233 shares on 5/16/2024Ownership: 5.442%Price T Rowe Associates Inc. MDBought 3,145 shares on 5/15/2024Ownership: 0.025%Vanguard Group Inc.Sold 13,469 shares on 5/10/2024Ownership: 4.203%Empowered Funds LLCBought 9,625 shares on 5/7/2024Ownership: 0.181%SG Americas Securities LLCSold 3,854 shares on 5/7/2024Ownership: 0.051%View All Insider TransactionsView All Institutional Transactions OVID Stock Analysis - Frequently Asked Questions Should I buy or sell Ovid Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OVID shares. View OVID analyst ratings or view top-rated stocks. What is Ovid Therapeutics' stock price target for 2024? 6 Wall Street research analysts have issued 1-year price objectives for Ovid Therapeutics' stock. Their OVID share price targets range from $3.50 to $11.00. On average, they anticipate the company's stock price to reach $8.08 in the next year. This suggests a possible upside of 160.8% from the stock's current price. View analysts price targets for OVID or view top-rated stocks among Wall Street analysts. How have OVID shares performed in 2024? Ovid Therapeutics' stock was trading at $3.22 at the beginning of the year. Since then, OVID shares have decreased by 3.7% and is now trading at $3.10. View the best growth stocks for 2024 here. When is Ovid Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 2nd 2024. View our OVID earnings forecast. How were Ovid Therapeutics' earnings last quarter? Ovid Therapeutics Inc. (NASDAQ:OVID) released its earnings results on Tuesday, May, 14th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. The company earned $0.15 million during the quarter, compared to analyst estimates of $0.11 million. Ovid Therapeutics had a negative trailing twelve-month return on equity of 53.62% and a negative net margin of 10,691.14%. What other stocks do shareholders of Ovid Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), SCYNEXIS (SCYX), Enphase Energy (ENPH), Gilead Sciences (GILD) and Novavax (NVAX). When did Ovid Therapeutics IPO? Ovid Therapeutics (OVID) raised $80 million in an initial public offering (IPO) on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers. Who are Ovid Therapeutics' major shareholders? Ovid Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BVF Inc. IL (5.44%), Vanguard Group Inc. (4.20%), Empowered Funds LLC (0.18%), Assenagon Asset Management S.A. (0.16%), SG Americas Securities LLC (0.05%) and BNP Paribas Financial Markets (0.05%). Insiders that own company stock include Amit Rakhit, Jason Tardio and Jeremy M Levin. View institutional ownership trends. How do I buy shares of Ovid Therapeutics? Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OVID) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.